SCHEMBL5687331

SCHEMBL5687331

CN(C(=O)Oc1ccc(NC(=O)c2ccc(C#N)cc2)cn1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 2/20 0.52
CXCR2 P25025 2/20 0.52
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP19A1 P11511 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
P4HTM Q9NXG6 1/20 0.44
LIPE Q05469 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647960 0.89 CXCR1 (0.56) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5687374 0.89 LMNA (0.52) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5689977 0.87 CXCR1 (0.55) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5687752 0.87 CXCR1 (0.66) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5690115 0.86 CXCR1 (0.54) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5649839 0.86 LIPE (0.55) CXCR1CXCR2CYP11B1CYP11B2KMT2A
SCHEMBL5649417 0.85 LMNA (0.56) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5647320 0.84 LIPE (0.59) CXCR1CXCR2LMNANPC1RAB9A
SCHEMBL5687182 0.84 CXCR1 (0.52) CXCR1CXCR2KMT2AMEN1LMNA
SCHEMBL5688363 0.84 CXCR1 (0.55) CXCR1CXCR2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160865-A1 Pyridinyl carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636205-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111031-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160865-A1 Pyridinyl carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636205-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111031-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160865-A1 Pyridinyl carbamates LIPE, PNLIP, LPL CXCR1 3306/4885CXCR2 4370/4885CYP11B1 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.